Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Keratoconjunctivitis sicca (Dry Eye) Treatment Pipeline Review H2 2016

Friday, October 14, 2016 2:53
% of readers think this story is Fact. Add your two cents.

(Before It's News)


‘Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H2 2016’, provides an overview of the Keratoconjunctivitis sicca (Dry Eye) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis sicca (Dry Eye), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and features dormant and discontinued projects.

Request a sample report @

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


- The report provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye) 
- The report reviews pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Keratoconjunctivitis sicca (Dry Eye) therapeutics and enlists all their major and minor projects 
- The report assesses Keratoconjunctivitis sicca (Dry Eye) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye) 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @



Key points in table of content

Table of Contents 2 
List of Tables 6 
List of Figures 7 
Introduction 8 
Global Markets Direct Report Coverage 8 
Keratoconjunctivitis sicca (Dry Eye) Overview 9 
Therapeutics Development 10 
Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) – Overview 10 
Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) – Comparative Analysis 11 
Keratoconjunctivitis sicca (Dry Eye) – Therapeutics under Development by Companies 12 
Keratoconjunctivitis sicca (Dry Eye) – Therapeutics under Investigation by Universities/Institutes 16 
Keratoconjunctivitis sicca (Dry Eye) – Pipeline Products Glance 17 
Late Stage Products 17 
Clinical Stage Products 18 
Early Stage Products 19 
Unknown Stage Products 20 
Keratoconjunctivitis sicca (Dry Eye) – Products under Development by Companies 21 
Keratoconjunctivitis sicca (Dry Eye) – Products under Investigation by Universities/Institutes 25 
Keratoconjunctivitis sicca (Dry Eye) – Companies Involved in Therapeutics Development 26 
AB2 Bio Ltd. 26 
Allergan Plc 27 
Ascendia Pharmaceuticals LLC 28 
Chong Kun Dang Pharmaceutical Corp. 29 
Digna Biotech, S.L. 30 
Dompe Farmaceutici S.p.A. 31 
HanAll Biopharma Co., Ltd. 32 
Herantis Pharma Plc 33 
Huons Co., Ltd. 34 
InSite Vision Incorporated 35 
Kala Pharmaceuticals, Inc. 36 
Kissei Pharmaceutical Co., Ltd. 37 
KPI Therapeutics, Inc. 38 
Kukje Pharmaceutical Industry Co., Ltd. 39 
Laboratoires Thea S.A. 40 
Lee’s Pharmaceutical Holdings Limited 41 
Lipicard Technologies Limited 42 
Merck & Co., Inc. 43 
Mimetogen Pharmaceuticals Inc. 44 
Mitotech S.A. 45 
Nanomerics Ltd 46 
Neuroptis Biotech 47 
Novaliq GmbH 48 
Ocular Therapeutix, Inc. 49 
Oculis ehf 50 
OncoNOx ApS 51 
Otsuka Holdings Co., Ltd. 52 
Parion Sciences, Inc. 53 
Quorum Innovations LLC 54 
RegeneRx Biopharmaceuticals, Inc. 55 
Rigel Pharmaceuticals, Inc. 56 
Samjin Pharmaceutical Co., Ltd. 57 
Santen Pharmaceutical Co., Ltd. 58 
Seikagaku Corporation 59 
Sucampo Pharmaceuticals, Inc. 60 
TearSolutions, LLC. 61 
TopiVert Ltd 62 
Xigen SA 63 
Keratoconjunctivitis sicca (Dry Eye) – Therapeutics Assessment 64 
Assessment by Monotherapy Products 64 
Assessment by Target 65 
Assessment by Mechanism of Action 69 
Assessment by Route of Administration 73 
Assessment by Molecule Type 75 
Drug Profiles 77 
AGN-223575 – Drug Profile 77 
AGN-232411 – Drug Profile 78 
Androgen Tears – Drug Profile 79 
AVA-3486 – Drug Profile 80 
AVX-012 – Drug Profile 81 
BRM-421 – Drug Profile 82 
cinhyaluronate sodium – Drug Profile 83 
Cis-Urocanic Acid – Drug Profile 84 
cyclosporine – Drug Profile 87 
cyclosporine – Drug Profile 90 
cyclosporine – Drug Profile 92 
cyclosporine – Drug Profile 93 
cyclosporine – Drug Profile 94 
cyclosporine – Drug Profile 95 
cyclosporine – Drug Profile 96 
cyclosporine – Drug Profile 97 
cyclosporine SR – Drug Profile 98 
dexamethasone acetate SR – Drug Profile 99 
diclofenac sodium – Drug Profile 104 
diquafosol tetrasodium – Drug Profile 105 
disitertide – Drug Profile 107 
Drugs to Agonize FPR2 for Dry Eye – Drug Profile 109 
Elate Ocular – Drug Profile 110 
HL-036 – Drug Profile 111 
HU-007 – Drug Profile 112 
hyaluronate sodium – Drug Profile 113 
ISV-101 – Drug Profile 114 
K-089 – Drug Profile 115 
KeraKlear – Drug Profile 116 
KJ-14003 – Drug Profile 117 
KL-7016 – Drug Profile 118 
KPI-190 – Drug Profile 119 
Lacripep – Drug Profile 120 
LME-636 – Drug Profile 121 
loteprednol etabonate – Drug Profile 122 
LT-4002 – Drug Profile 125 
LT-4003 – Drug Profile 126 
NOP-3 – Drug Profile 127 
NOP-5 – Drug Profile 128 
Nov-03 – Drug Profile 129 
OC-301 – Drug Profile 130 
OX-1001 – Drug Profile 131 
ozagrel – Drug Profile 132 
P-321 – Drug Profile 133 
plastoquinone decyl triphenylphosphonium bromide – Drug Profile 135 
PPL-003 – Drug Profile 137 
Qi-204 – Drug Profile 139 
R-348 – Drug Profile 140 
rebamipide – Drug Profile 142 
Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology – Drug Profile 144 
RGN-259 – Drug Profile 146 
RP-101 – Drug Profile 153 
RU-101 – Drug Profile 154 
SA-001 – Drug Profile 156 
SJP-002 – Drug Profile 157 
Small Molecule to Agonize Glucocorticoid Receptor for Dry Eye – Drug Profile 158 
ST-266 – Drug Profile 159 
tadekinig alfa – Drug Profile 161 
tavilermide hydrochloride – Drug Profile 162 
TOP-1630 – Drug Profile 164 
XG-104 – Drug Profile 165 
ZK-003 – Drug Profile 166 
zucapsaicin – Drug Profile 167 
Keratoconjunctivitis sicca (Dry Eye) – Dormant Projects 169 
Keratoconjunctivitis sicca (Dry Eye) – Discontinued Products 175 
Keratoconjunctivitis sicca (Dry Eye) – Product Development Milestones 176 
Featured News & Press Releases 176 
Appendix 187 
Methodology 187 
Coverage 187 
Secondary Research 187 
Primary Research 187 
Expert Panel Validation 187 
Contact Us 187 
Disclaimer 188

Get this report @


Contact US:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.